Business Description
Renovaro Inc
NAICS : 325414
SIC : 2834
ISIN : US29350E1047
Description
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.2 | |||||
| 3-Year EPS without NRI Growth Rate | 14.8 | |||||
| 3-Year FCF Growth Rate | 36 | |||||
| 3-Year Book Growth Rate | -36.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.89 | |||||
| 9-Day RSI | 43.43 | |||||
| 14-Day RSI | 45.69 | |||||
| 6-1 Month Momentum % | -78.07 | |||||
| 12-1 Month Momentum % | -84.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.07 | |||||
| Quick Ratio | 0.07 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.7 | |||||
| Shareholder Yield % | -3.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -92.19 | |||||
| ROA % | -73.41 | |||||
| ROIC % | -23.6 | |||||
| 3-Year ROIIC % | -53.95 | |||||
| ROC (Joel Greenblatt) % | -5073.9 | |||||
| ROCE % | -84.41 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.6 | |||||
| EV-to-EBIT | -1.07 | |||||
| EV-to-EBITDA | -1.07 | |||||
| EV-to-FCF | -7.6 | |||||
| Earnings Yield (Greenblatt) % | -93.46 | |||||
| FCF Yield % | -13.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Renovaro Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.731 | ||
| Beta | 0 | ||
| Volatility % | 105.81 | ||
| 14-Day RSI | 45.69 | ||
| 14-Day ATR (€) | 0.070435 | ||
| 20-Day SMA (€) | 0.478225 | ||
| 12-1 Month Momentum % | -84.79 | ||
| 52-Week Range (€) | 0.335 - 4.44 | ||
| Shares Outstanding (Mil) | 156.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Renovaro Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Renovaro Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Renovaro Inc Frequently Asked Questions
What is Renovaro Inc(FRA:2Q5)'s stock price today?
The current price of FRA:2Q5 is €0.43. The 52 week high of FRA:2Q5 is €4.44 and 52 week low is €0.34.
When is next earnings date of Renovaro Inc(FRA:2Q5)?
The next earnings date of Renovaro Inc(FRA:2Q5) is 2024-11-14 Est..
Does Renovaro Inc(FRA:2Q5) pay dividends? If so, how much?
Renovaro Inc(FRA:2Q5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers